A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
The purpose of this study is to test if TSND-201 is safe and effective in treating symptoms of PTSD. Approximately 300 adults, at least 18 years of age, with PTSD will participate in this research study.
Study phase: III
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
Aged 18 years
PTSD diagnosis
Primary disease category: Mental Health
Secondary disease categories: Mental Health
Sponsor: Transcend Therapeutics
Protocol number: TSND201-PTSD-301
Projected enrollment dates: July 2026 to July 2027
Official study title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/N/A